

# Fiscal Year 2010 Annual Review of Byetta®/Victoza®

Oklahoma Health Care Authority  
April 2011

## Current Prior Authorization of Byetta®/Victoza®

There is a step therapy edit in the system to detect metformin, sulfonylurea, or thiazolidinedione usage for at least 30 days within the previous 120 days. Members without sulfonylurea or metformin claims in the system would be eligible to submit a paper petition.

Authorization is based on the following criteria:


1. Patients must have Type 2 diabetes and currently taking metformin, sulfonylurea, thiazolidinediones, or a combination, for at least 90 days within the last 180 days, and have not achieved adequate glycemic control.
2. Clinical exception may be allowed if prescribed by an endocrinologist.
3. Quantity limit of 3 cartridges per 30 days applies (3.6 mls & 7.2mls) for Byetta®.
4. Quantity Limit of 3 penpaks (9mls) per 30 days for Victoza®.

## Utilization of Byetta®/Victoza®


### Comparison of Fiscal Year Utilization

Fiscal Year	Members	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2009	206	805	\$217,612.21	\$270.33	\$7.98	1,872	27,260
2010	220	857	\$246,762.75	\$287.94	\$8.30	2,320	29,748
% Change	6.80%	6.50%	13.40%	6.50%	4.00%	23.90%	9.10%
Change	14	52	\$29,150.54	\$17.61	\$0.32	448	2,488

### Demographics of Members Utilizing Byetta®/Victoza®: FY 2010



### Prescribers of Byetta®/Victoza®: FY 2010



### Utilization Details

Medication	Claims	Units	Days	Members	Paid	Units/Day	Claims/Member	Per-diem
BYETTA 10MCG INJ	613	1,681	21,130	141	\$179,313.19	0.08	4.35	\$8.49
BYETTA 5MCG INJ	204	282	7,139	87	\$52,388.16	0.04	2.34	\$7.34
VICTOZA 6MG/ML INJ	40	357	1,479	29	\$15,061.40	0.24	1.38	\$10.18
<b>Totals</b>	<b>857</b>	<b>2,320</b>	<b>29,748</b>	<b>220*</b>	<b>\$246,762.75</b>	<b>0.08</b>	<b>3.9</b>	<b>\$8.30</b>

\*Total Number of Unduplicated Members

### Prior Authorization of Byetta®/Victoza® Products

There were a total of 101 petitions submitted for this category during fiscal year 2010. There are automated computer edits to detect metformin, sulfonylurea, or thiazolidinediones in member’s claims history and generate prior authorizations at the point of sale where possible. The following shows the status of the submitted petitions.

### Status of Petitions for Byetta®/Victoza®: FY 2010



### Conclusion and Recommendations

The College of Pharmacy recommends no changes to this category at this time.